Evidence map›Paper›PMID 26941019›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2016

Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis.

Jing Cao, Brian T Steffen, Matthew Budoff, Wendy S Post, George Thanassoulis, Bryan Kestenbaum, Joseph P McConnell, Russell Warnick, Weihua Guan, Michael Y Tsai

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Lowering of Lipoprotein(a) with Olpasiran.Cardiovascular & hematological disorders drug targets · 2026
    Review
  9. Observational
  10. Article
  11. Review
  12. Novel Circulating Biomarkers in Aortic Valve Stenosis.International journal of molecular sciences · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Lipoprotein(a): Emerging insights and therapeutics.American journal of preventive cardiology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jing CaoFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Brian T SteffenFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Matthew BudoffFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Wendy S PostFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
George ThanassoulisFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Bryan KestenbaumFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Joseph P McConnellFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Russell WarnickFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Weihua GuanFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.).
Michael Y TsaiFrom the Department of Laboratory Medicine and Pathology (J.C., B.T.S., M.Y.T.), Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Medicine, University of California, Los Angeles (M.B.); Department of Medicine, John Hopkins University, Baltimore, MD (W.S.P.); Department of Medicine, McGill University, Montreal, Québec, Canada (G.T.); Division of Nephrology, Kidney Research Institute, University of Washington, Seattle (B.K.); and Health Diagnostics Laboratory, Richmond, VA (J.P.M., R.W.). tsaix001@umn.edu.
Johns Hopkins University · USUniversity of California, Los Angeles · USUniversity of Washington · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Ventricular Size and Valve Calcification Measures by CTR01HL071739 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI BUDOFF, MATTHEW J · 2003 to 2010
$2.0M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095166 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1999 to 2001
$758k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · HC · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MOYSES A · 1999 to 2000
$694k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095161 · HC · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN · 1999 to 2001
$642k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095165 · HC · WAKE FOREST UNIVERSITY · PI BURKE, GREGORY L · 1999 to 2001
$616k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095160 · HC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAAD, MOHAMMED F · 1999 to 2001
$592k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095164 · HC · NORTHWESTERN UNIVERSITY · PI LIU, KIANG JOHN · 1999 to 2001
$511k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095163 · HC · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FOLSOM, AARON R · 1999 to 2001
$443k
Enhancing immune reconstitution after implantation of postnatal allogeneic thymusR21HL095165 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2008 to 2009
$440k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095168 · HC · JOHNS HOPKINS UNIVERSITY · PI BLUEMKE, DAVID A. · 1999 to 2000
$375k
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL071739NIH HHS HHSN263201500003I
6 · The paper itself

Abstract

objectiveLipoprotein(a) [Lp(a)] is a risk factor for calcific aortic valve disease (CAVD) but has not been evaluated across multiple races/ethnicities. This study aimed to determine whether Lp(a) cutoff values used in clinical laboratories to assess risk of cardiovascular disease identify subclinical CAVD and its severity and whether significant relations are observed across race/ethnicity. APPROACH AND

resultsLp(a) concentrations were measured using a turbidimetric immunoassay, and subclinical CAVD was measured by quantifying aortic valve calcification (AVC) through computed tomographic scanning in 4678 participants of the Multi-Ethnic Study of Atherosclerosis. Relative risk and ordered logistic regression analysis determined cross-sectional associations of Lp(a) with AVC and its severity, respectively. The conventional 30 mg/dL Lp(a) clinical cutoff was associated with AVC in white (relative risk: 1.56; confidence interval: 1.24-1.96) and was borderline significant (P=0.059) in black study participants (relative risk: 1.55; confidence interval: 0.98-2.44). Whites with levels ≥50 mg/dL also showed higher prevalence of AVC (relative risk: 1.72; confidence interval: 1.36-2.17) than those below this level. Significant associations were observed between Lp(a) and degree of AVC in both white and black individuals. The presence of existing coronary artery calcification did not affect these associations of Lp(a) and CAVD. There were no significant findings in Hispanics or Chinese.

conclusionsLp(a) cutoff values that are currently used to assess cardiovascular risk seem to be applicable to CAVD, but our results suggest race/ethnicity may be important in cutoff selection. Further studies are warranted to determine whether race/ethnicity influences Lp(a) and risk of CAVD incidence and its progression.

Indexed as

Black or African AmericanWhite PeopleAgedAged, 80 and overAortic ValveAortic Valve StenosisAsymptomatic DiseasesAtherosclerosisBiomarkersCalcinosisCross-Sectional StudiesFemaleHumansImmunoassayLipoprotein(a)MaleBiomarkersLipoprotein(a)Phosphatesaortic valve, calcification ofatherosclerosisimmunoassayprevalencerisk factor

Identifiers

PMID26941019
PMCPMC4850093
OpenAlexW2291663719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.